• Home
  • NEW DAY MEDICINE
  • 3 (31) 2020
  • 53 -3 (31/2) 2020 — Azizova D.SH.,Azizov A.M., — DYNAMIC CHANGES IN BIOCHEMICAL MARKERS OF BONE METABOLISM DURING TREATMENT IN WOMEN OF REPRODUCTIVE AGE WITH HYPOESTROGENIA

53 -3 (31/2) 2020 — Azizova D.SH.,Azizov A.M., — DYNAMIC CHANGES IN BIOCHEMICAL MARKERS OF BONE METABOLISM DURING TREATMENT IN WOMEN OF REPRODUCTIVE AGE WITH HYPOESTROGENIA

DYNAMIC CHANGES IN BIOCHEMICAL MARKERS OF BONE METABOLISM DURING TREATMET IN WOMEN OF REPRODUCTIVE AGE WITH HYPOESTROGENIA

Azizova D.SH. -State Institution Republican specialized scientific- practical medical center of obstetrics and gynecology, State Institution Republican specialized scientific and practical Medical Center of traumatology and orthopedics.

Azizov A.M. -State Institution Republican specialized scientific- practical medical center of obstetrics and gynecology, State Institution Republican specialized scientific and practical Medical Center of traumatology and orthopedics.

Azizova G.D. -State Institution Republican specialized scientific- practical medical center of obstetrics and gynecology, State Institution Republican specialized scientific and practical Medical Center of traumatology and orthopedics.

Ismoilova Z.I. -State Institution Republican specialized scientific- practical medical center of obstetrics and gynecology, State Institution Republican specialized scientific and practical Medical Center of traumatology and orthopedics.

Resume

In women of reproductive age with hypoestrogenia of various origins, significant changes in bone metabolism occur, characterized by the predominance of the destruction process over the process of bone synthesis. Namely, the value of р-Crosslaps was 1.5 times higher than normal (0.83+ 0.03 ng / ml), approximately half of the examined women were found to have elevated levels of P1NP, while markers of bone formation remained within the normal range. As a result of three months of antiresorptive treatment in these women, the level of markers of bone metabolism changed slightly, markers of resorption and vitamin D indicators approached normal values.

Key words: hypoestrogenism, biochemical markers of the skeletal system, reproductive age, osteoporosis.

First page

229

Last page

232

For citation: Azizova D.SH.,Azizov A.M., Azizova G. D.,Ismoilova Z.I. Dynamic changes in biochemical markers of bone metabolism during treatment in women of reproductive age with hypoestrogenia//New Day in Medicine 3(31)2020 229-232 https://cutt.ly/CxIYVIE

List of Refereces

  1. Кузнецова И.В., Успенская Ю.Б. Остеопороз у молодых жен­щин со стойким дефицитом эстротюв. Ж // Российский вестник аку0ера-гинеколога. – 2009.- №3.
  2. Положаева И.В., Алиякпаров М.Т. Актуальность проблемы остеопороза в молодом возрасте и его ранней современной диашостики // Международный жур^ал прикладных и фун­даментальных исследований. – 2018. – № 2. – С. 115-120;
  3. Eastell R, O‘Neill T.W., Hofbauer L.C., Langdahl B., Reid I.R., Gold D.T., Cummings S.R. Postmenopausal osteoporosis. Nature reviews Disease primers. -2016. -Vol.2.-№16069.
  4. Macari S, Ajay Sharma L, Wyatt A, Knowles P, Szawka R.E., Garlet G.P., Grattan D.R., Dias G.J., Silva T.A. Osteoprotective effects of estrogen in the maxillary bone depend on ERalpha. J Dent Res. – 2016. -Vol. 95. -№ 6.-P. 689-696.
  5. Eastell R., Christiansen C., Grauer A. et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis // JBMR. -2011.- Vol. 26. -№ 3.- P. 530-537.
  6. Sahana Shetty, Nitin Kapoor, Joseph DianBondu, et al. Bone turnover markers: emerging tool in the management of osteoporosis // Indian Journal EndocrinolMetab. – 2016. -Vol. 20. -№ 6.-P. 846-852.
  7. Мкртумян, А. М. Состояния метаболизма углеводов и жиров у пациекгок с гипоэстрогетаыми формами ановуляции на фоне долговременной заместителыюй гормональной терапии / А. М. Мкртумян, М. А. Геворкян. Н. Б. Чагай // Проблемы реп­родукции. – 2011. – № 3. – С. 43-49.
  8. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008;42:467-75.
  9. Lorentzon M, Cummings SR. Osteoporosis: the evolution of a diagnosis. J Intern Med. 2015; 277:650-61.
  10. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). ArchOsteoporos. 2013; 8:136.
53-229-232-3-31-2020-

file

download